Startup grabbed headlines in late 2016 when it raised US$41 million in a series-B venture capital financing round
Dr. David Stojdl
An Ottawa biotech startup has received a US$41-million injection of venture capital to further develop its groundbreaking treatments that use the body’s own immune system to battle cancer.
